LuciQuiza 17.7 mg
Original price was: $700.00.$637.16Current price is: $637.16.
LuciQuiza is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
In Stock
Description
COMPOSITION:
Each film-coated tablet contains Quizartinib dihydrochloride 20 mg equivalent to Quizartinib…………………………………17.7mg.
INDICATION:
LuciQuiza is a kinase inhibitor indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
DOSAGE AND USE:
• Take LuciQuiza tablets orally once daily with or without food at approximately the same time each day.
• See Full Prescribing Information for recommended LuciQuiza dosage regimen and dosage modifications.
STORAGE:
In a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of reach of Children. Do not administer LuciQuiza during Pregnancy and Lactation.
Reviews
There are no reviews yet.